Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Reestablishes Imaging Drugs Committee, Citing Application Surge

Executive Summary

The increasing number of new medical imaging drugs FDA is asked to review has led the agency to reestablish an advisory committee devoted exclusively to them.

You may also be interested in...



Ultrasound Contrast Agents Need New Safety Trial After Discouraging Advisory Cmte.

An FDA advisory panel member suggests having a third party design future safety studies for ultrasound contrast agents.

Ultrasound Contrast Agents Need New Safety Trial After Discouraging Advisory Cmte.

An FDA advisory panel member suggests having a third party design future safety studies for ultrasound contrast agents.

Lots Of Activity In Forest Pipeline, But Can The Specialty Pharma Ever Put Lexapro Behind It?

Forest Laboratories, Inc. has late-stage products lined up in its pipeline to help fill the gap left when Lexapro and Namenda go generic, but the burden on a specialty pharma to differentiate its products is a heavy one these days, and it will be a struggle to the finish to convince investors the cup is half full.

Related Content

Topics

UsernamePublicRestriction

Register

PS053377

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel